secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001493152-25-018252
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Q3 net loss $877K; pursues asset divestment for Cullgen merger
------------------------------------------------------------------------

- Net loss $877K ($0.24 per share); revenues $0 vs $0.4M YoY; cash $4.8M sufficient into Q4 2026.
- Pursuing divestment of iSPERSE technology and clinical programs (PUR3100, PUR1800, PUR1900) ahead of proposed Cullgen merger.
- Proposed merger with Cullgen stockholder-approved; closing subject to Nasdaq & China regulatory approval.
- R&D expenses fell to <$0.1M; G&A down to $0.9M due to winddown and cost cuts.
- PUR3100 Phase 2 ready for acute migraine; PUR1900 partner Cipla advancing Phase 3 in India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/0001493152-25-018252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315225018252/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-018252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer